Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial ...

Camp4 Therapeutics Corporation’s CAMP share price has dipped by 18.47%, which has investors questioning if this is right time to buy.

German biotech Akribion Therapeutics has emerged from stealth with 8 million euros ($9 million) in seed funding to accelerate ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Boston, USA-based biotech Averna Therapeutics (formerly known as Exsilio Therapeutics), revealed yesterday that it has ...

Camp4 Therapeutics Corporation’s CAMP share price has surged by 18.71%, which has investors questioning if this is right time to sell.

No significant safety or dose limiting toxicities reported PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results BOSTON, Feb. 6 ...